CureVac (CVAC) to Release Quarterly Earnings on Wednesday

CureVac (NASDAQ:CVAC - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.27 per share and revenue of $20.58 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Price Performance

Shares of NASDAQ CVAC traded down $0.08 during trading hours on Friday, reaching $3.12. 282,787 shares of the stock traded hands, compared to its average volume of 809,336. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. CureVac has a 52-week low of $2.22 and a 52-week high of $5.28. The company's 50-day simple moving average is $3.09 and its two-hundred day simple moving average is $3.16. The company has a market capitalization of $698.51 million, a P/E ratio of 5.67 and a beta of 2.48.

Analyst Ratings Changes

Separately, JMP Securities reissued a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research note on Friday, February 14th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.